Captor Therapeutics to Present at the 3rd European Protein Degradation Congress in September

      14.09.2021

       

      Wrocław, Poland, September 14, 2021 - Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of novel protein degradation drugs for cancer and autoimmune diseases, today announced that Chief Executive Officer Dr. Tom Shepherd will present at the Third European Protein Degradation Congress, being held virtually from 21st to 23rd September, 2021.

      His presentation, entitled "Captor Therapeutics Selective OptigradeTM Platform", will take place on Tuesday 21st September at 16:30 pm CET. A video replay of the presentation will be available on the congress platform for registered delegates. Further information on the conference can be found at this link.

      A copy of the slides used in the presentation will be available on Captor Therapeutics’ website on the day of the presentation.

       

       

      About Captor Therapeutics

      Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide optimal medical benefit. Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases. 

       

      More information on Captor Therapeutics is available at: http://www.captortherapeutics.com

      LinkedIn: @CaptorTherapeutics

      Twitter: @CaptorTherapeu1

       

      For further information, please contact:

      Polish Media and Investor relations:

      Point of View

      Jakub Radzewicz

      +48 601 155 582

       

      International Investor Relations:

      LifeSci Advisors

      Guillaume van Renterghem

      +41 (0)76 735 01 31

      gvanrenterghem@lifesciadvisors.com